Originally published as JCO Early Release 10.1200/JCO.2003.04.115 on October 27 2003

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Coiffier, B. Articles by Herbrecht, R. Search for Related Content PubMed PubMed Citation Articles by Coiffier, B. Articles by Herbrecht, R. Related Articles Related Correspondence Social Bookmarking                            What's this?

Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin’s Lymphoma: Results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study

From the Centre Hospitalier Lyon-Sud, Pierre-Bénite; Hôpital Saint-Louis, Paris; Centre Hospitalier Universitaire de Brabois, Vandoeuvre les Nancy; Institut Gustave Roussy, Villejuif; Centre Becquerel, Rouen; Hôpital Bon Secours, Metz; Centre Hospitalier du Bocage, Dijon; Centre Hospitalier de Nîmes, Nîmes; Hôpital Henri Mondor, Créteil; Hôpital de Hautepierre, Strasbourg, France; and Université Catholique de Louvain-Mont Godinne, Yvoir, Belgium.

Address reprint requests to B. Coiffier, MD, Hématologie, CH Lyon-Sud, 69495 Pierre-Bénite, France; e-mail: bertrand.coiffier{at}chu-lyon.fr.

Purpose: Hyperuricemia and tumor lysis syndrome are well-known complications during induction treatment of aggressive non-Hodgkin’s lymphomas (NHLs). Usual prophylaxis and treatment of hyperuricemia consist of hydration, alkalinization, and administration of allopurinol. This study was designed to evaluate the efficacy and the safety of rasburicase (recombinant urate oxidase) in adult patients with aggressive NHL during their first cycle of chemotherapy.

Patients and Methods: A total of 100 patients from Groupe d’Etude des Lymphomes de l’Adulte centers, with diffuse large B-cell lymphoma (n = 79); anaplastic large-cell lymphoma (n = 6); peripheral T-cell lymphoma (n = 8); transformation of indolent lymphoma (n = 5); Burkitt’s lymphoma (n = 1); and lymphoblastic lymphoma (n = 1) were enrolled from May 2001 to June 2002. Before chemotherapy, 66% of patients had elevated lactate dehydrogenase (LDH), including 28% with LDH above 1,000 U/mL. Eleven percent of patients were hyperuricemic (uric acid [UA] > 450 mmol/L or > 7.56 mg/dL). Rasburicase 0.20 mg/kg/d intravenously for 3 to 7 days was started the day before or at day 1 of chemotherapy. UA levels were measured 4 hours after rasburicase injection, then daily during treatment.

Results: All patients responded to rasburicase, as defined by normalization of UA levels maintained during chemotherapy. The control of UA was obtained within 4 hours after the first injection of the drug. Creatinine levels and other metabolites were also controlled with the administration of rasburicase. No patient exhibited increased creatinine levels or required dialysis during chemotherapy.

Conclusion: Rasburicase is the treatment of choice to control UA and prevent tumor lysis syndrome in adult patients with aggressive NHL.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Is Rasburicase Needed for Prevention of Tumor Lysis Syndrome During Treatment of Less Aggressive Hematolymphoid Malignancies?
  Syed Z.A. Zaidi and Mahmoud Aljurf
  JCO 2004 22: 3430-3431 [Full Text]

This article has been cited by other articles:

				P. Tosi, G. Barosi, C. Lazzaro, V. Liso, M. Marchetti, E. Morra, A. Pession, G. Rosti, A. Santoro, P. L. Zinzani, et al. Consensus conference on the management of tumor lysis syndrome Haematologica, December 1, 2008; 93(12): 1877 - 1885. [Abstract] [Full Text] [PDF]

				B. Coiffier, A. Altman, C.-H. Pui, A. Younes, and M. S. Cairo Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review J. Clin. Oncol., June 1, 2008; 26(16): 2767 - 2778. [Abstract] [Full Text] [PDF]

				J. Hochberg and M. S. Cairo Tumor lysis syndrome: current perspective Haematologica, January 1, 2008; 93(1): 9 - 13. [Full Text] [PDF]

				M Trujillo and M Morales Rasburicase-induced fatal respiratory arrest? Ann. Onc., February 1, 2007; 18(2): 399 - 400. [Full Text] [PDF]

				L. A Browning and J. A Kruse Hemolysis and Methemoglobinemia Secondary to Rasburicase Administration Ann. Pharmacother., November 1, 2005; 39(11): 1932 - 1935. [Abstract] [Full Text] [PDF]

				G. Thiery, E. Azoulay, M. Darmon, M. Ciroldi, S. De Miranda, V. Levy, F. Fieux, D. Moreau, J. R. Le Gall, and B. Schlemmer Outcome of Cancer Patients Considered for Intensive Care Unit Admission: A Hospital-Wide Prospective Study J. Clin. Oncol., July 1, 2005; 23(19): 4406 - 4413. [Abstract] [Full Text] [PDF]

				B. Vogt Urate oxidase (rasburicase) for treatment of severe tophaceous gout Nephrol. Dial. Transplant., February 1, 2005; 20(2): 431 - 433. [Full Text] [PDF]

				B. D. Humphreys, R. J. Soiffer, and C. C. Magee Renal Failure Associated with Cancer and Its Treatment: An Update J. Am. Soc. Nephrol., January 1, 2005; 16(1): 151 - 161. [Full Text] [PDF]

				B. Coiffier In Reply: J. Clin. Oncol., August 15, 2004; 22(16): 3431 - 3432. [Full Text] [PDF]

				S. Z.A. Zaidi and M. Aljurf Is Rasburicase Needed for Prevention of Tumor Lysis Syndrome During Treatment of Less Aggressive Hematolymphoid Malignancies? J. Clin. Oncol., August 15, 2004; 22(16): 3430 - 3431. [Full Text] [PDF]